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Recent experimental sndies show that the op(oid system is impor-
tant to the palhophysioluny of cardiovascular impairment in
congestive heart failure . Plasma beta-endorphin levels were mea .
sured in 37 patients with congestive heart failure and compared
with those of 21 age . and gender-mulched normal subjects. The
relation of plasma beta-endorphin levels and rmdiac function at
rest and
exercise
capacity was assessed in 17 of the patients with
diluted cardlomyopathy . Exercise capacity was determined by
symptom-limited maximal treadmill exercise with expired gas
amlysis. Plasma bela-endorlahtn levels were elevated and eorre-
toled with the patients' New York Heart Association functional
®rim status (control
: 14 .0 s 4
.4 p)rni ; class 11
: 17.9 x
3.6 pgfnd; class HE 28 .3 ± 8 .8 pglml ; doss IV : 46 .7 ± 14 .6 pgiml .
mean x SD). No relation was found between plasma beta .
endorphin levels and tell ventricular systolic performance as
Endogenous opioids have analgesic . euphoric and addictive
effects (1-3) . It has become clear that endogenous opioids
are essential to regulation of the cardiovascular system (4 .51
Opioid peptides are found at sites related to autonomic
actions and opioid receptors are densely covecncrated in
areas near the cardiovascular centers of the brain and
hypothalamus (4)
.
Endogenous opioids are involved in the
pathogenesis of various types of shock, such as hentorrhag ;c
shock, as well as hypertension I4-7) . They also affect
respiration and the secretion of vasepressin and other hot-
maws (4,5,8).
Seta-endorphin is one of the alajor endugen(Jus opioids
and is derived from pro aptomelanoconm, found in the
pituitary It-5.91. Liang er al . 116.11) reported that plasma
levels of beta-endorphin are elevated in dogs with chronic
congestive heart failure produced by pulmonary artery con-
striction and tricuspid valve avulsion . They also showed that
the administration of the opioid receptor antagonist nal-
merene resulted in improvement of the impaired hemody-
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assessed 'us S1-made and nleppler eehenrdiouap hy
. Plasma
beta endorphin levels were negatively rarretated with order
wilt-
A
determined by Doppler echneardiography and positively
correlated with systemic vascular resistance (r = -6.733, r =
0 .147 . respectively . froth p < 0,901) . but nal correlated with calf
blood How as measured by a plethysteography . A goad rurrelafion
was round between plasoe bela-endorphin levels at rest and
exercise capacity. The correladoos with pear oxygen ronsunp
lion, anaerobic threshold . and peak r seepeessme produce were
r = -0 .721 . -0.672, and -0.674, respectively (p < 0.81) .
The data show that plasma beta-endorphin levels are elevated
in patients with congestive heart failure and reflect, to mote
degree, the soverhy of the disease .
(J Am Coll Curdiol 1991 ;17.53-8)
namics in those dogs and suggested that endogenous opioids
contribute to circulatory dysfunction in congestive heart
failure . Clinically, however . the role of endogenous opioids
in congestive heap failure remains unclear . No report . looter
know, edge, has focused attnation evil beta-endorphin in pa-
tients with Cangesti,c heart failure .
Tire purposes of cue present sends were to determine 1)
is saIler plasma beta-endorphin levels are elevated in pa-
ilents with congestive heart failure, and 2) the relation of
plasma beta-endorphin levels to the severity of Cardiovascu-
lar abnormality and exercise capacity in these patients .
Methods
Study patients . The study was performed in 37 patients
with congestive heart failure 129 men and 8 women) aced 22
to 77 year I mean ± SD, 56 = 131 . The underlying causes of
heart fai:urc were idiopathic dilated cardiomyopathy in 19
.
old myocardial infarction in 7 and valvular disease in 11 . All
patients had been symptomatic for at least 2 months and
were treated with digitalis and diurclics
. No patients had
received adrenergic agonists or antagonists
. Capiopril had
been given to four patents and was withdrawn in two of
them before this study
. Patients with a recent myocardial
infarction i<3 months) and symptomatic angina pectoris
were excluded . Twenty-one healthy subjects without cardio-
vascular disease )16 men and 5 women) aged 26 to 72 years
n735-10979IfSa I)
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(mean 50 ± 12) served as the control group . The study was
approved by the Institutional Human Research Review
Committee and each patient gave informed consent .
Plasma bemtndorphla levels . These were taken between
7:00 and R :00 AM and were regarded as basal levels, The
day-today variability
of
basal plasma beta-endorphin levels
was determined in six control subjects and four patients with
heart failure under relatively stable clinical conditions. Se-
quential blood sampling was performed en 2 days separated
by I week .
In all patients,
the basal
plasma hem-endorphin lrveis
were assessed in relation au fwtcuunal cardiac status, deter-
mined according to the criteria of the New York Heart
Association based on symptoms (121 . To evaluate changes in
endorphin levels with respect to changes in cardiac status
with time in individual patients, we measured plasma beta-
cedorfhin at baseline on admission and sequentially during
follow-up periods of 2 months in eight patients.
Echocardiography . For detailed assessment of the role of
beta-endorphins in the cardiovascular system, noninvasive
studies of cardiac function were performed in the patients
with dilated cardiomyopathy. After blond sampling, two-
dimensional and pulsed Doppler echocardiography was per-
formed. The studies were performed with the subjects in a
semilateral position, The examination was carried out by
using a B-mode image with the Toshiba SSH 65A system and
2
.5 or 3 .5 MHz transducer . Among the 19 patients with
dilated cardiomyopathy, two were excluded from the study
because of concomitant high-grade mitral regurgitation . Left
ventricular end-diastolic and end-systolic dimensions were
measured below the tips of the mitral leallets . By Doppler
echocardiography, duration of aortic low was used as the
left ventricular ejection time and the period from the begirr
ping of the electrvcardragraphic QRS cunrpkx to lkv onset
of sonic flaw as the pre-ejection period . Fractional shorten-
ing (FS) of the left ventricle was calculated as (LVDd -
LVDs)ILVDd x 100. Mean rate of circumferential shorten-
ing (Vcfl (circis) was calculated as (LVDd - LVDa)!
(LVDd x LVET), where LVDd and LVDs = left ventricular
end-diastolic and end-systolic dimension, respectively, and
LVET = left ventricular ejection time . Cardiac output was
determined by the Doppler left ventricular outflow method
from the apical five-chamber view .
Plethysmography . Calf blood flow was obtained by
strain-gauge plethysmography with the venous occlusion
technique (13)- Blood pressure was measured with a sphyg .
momanometcr. Systemic vascular resistance was calculated
by dividing the mean blood pressure (diastolic pressure plus
one-third of the pulse pressure) by cardiac output,
Exercise capacity . Maximal exercise capacity was esti-
mated in 16 of 17 patients with dilated cardiomyopathy in the
postabsorptive state on the day of the noninvasive study .
One patient was symptomatic at rest (class IV) and could not
exercise. The patients underwent upright treadmill exercise
to a symptom-limited maximum of dyspnea or fatigue . All
patients studied were familiarized with the exercise program
JACC Vot. rr, Ne. I
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before the study . The exercise was carried eel in the
following 2-min stages : I = 1
.5 kmlh, 175E grade ; 2 = 2 kWh,
0% grade ; 3 = 2 kmlh, 5% grade; 4 = 2 .5 kMh, 5% grade;
S = 3 kWh,
a% grade ; 6 = 3 .5 km/h, 10% grade ; 7 = 4 kndh,
10% grade
;
a = 4.5 kWh, 10% grade ; 9 = 5 km/h, 13% grade;
and 10 = 5 .5 kmh, 15% grade. Expired gas was collected
and analyzed continuously with on-line breath-by-breath
computer data acquisition (Westron Co.).
Using the on-line
computer, oxygen consumption (VO2), minute ventilation
(VE), carbon dioxide production (VC02), end-tidal oxygen
partial pressure,
end-tidal
carbon dioxide partial pressure
and respiratory quotient (RQ) were measured . Heart rate,
blood pressure and ECGs were monitored throughout the
exercise test . As an expression of exercise capacity
. the
rate-pressure product at the time of peak VO2 was calcu-
lated . The anaerobic threshold was defined based on the
criteria of Simonton et al . (14) .
Measuremealeofplasombeta-endrrphio. Blood sampling
for measurements of basal plasma beta-endorphin was done
with the patient in the supine position using an indwelling 18
gauge catheter inserted in an antecuhital vein . Blood was
taken 30 min after the catheter was placed and immediately
introduced into chilled tubes containing EDTA anticoagu-
lant. Blood was centrifuged for 15 min at 4°C at 760 g and
plasma was stored at -40°C until use . One milliliter of
plasma was concentrated and beta-endorphin was extracted
using a column and antibody-coated Sepharose particles
.
Beta-endorphin was eluted with 0 .025 N HC1 from the
column and measured by radioimmunoassay (INCSTAR
Co.) . In this assay system, cross reactivity with beta-
liputropin was less than 5% . Replicate measurements at our
laboratory of plasma beta-endorphin had coefficients of
variations of 10%.
Statistics. All values were expressed as mean values t
SD. A comparison of brta-endorphin levels among groups
was made by one-way analysis of variunee with Schefl'd's
multiple comparison test. Linear regression analysis using
the least-squares method was conducted to compare plasma
beta-endorphin levels with hemodynamie measurements and
exercise capacity. A p value of w0 .05 was considered
statistically significant.
Results
Plasma bela•o dorphin levels. The mean basal plasma
beta-endorphin levels in control subjects was 14.0 ±
4.4 pglml. No control subject had a basal level exceeding
20 pgtml . The mean level in patients with congestive heart
failure, was 30
.8 '
15 .9 pgrmt, significantly higher than that
in control subjects (p < 0.01) . Plasma beta-endorphin levels
were found to be relatively stable throughout 1 week, the
variation being within 20% in each subject .
The patients were divided into subgroups on the basis of
theirfunctional cardiac status (12) .
No patient was in class I
.
The plasma beta-endorphin levels were found to correlate
with the functional cardiac status. Basal plasma beta-
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Fig= 1 . Functional cardiac status (New York Heart Association
1NYHAl classification) versus plasma beta-endorphin levels in 21
control subjects and 37 patients with congestive heap failure . The
mean ± SD is indicated by the solid bar for each functional class.
p < 0
.01
; 59 .0
0 .05 .
endorphin levels in patients with classes III and IV heart
failure were significantly higher than those in control sub-
jects (Fig. 1) . In individual patients in whom seyuc:aial
follow-up blood sampling was performe'f
. plasma beta-
endorphin levels changed with alteration in the patient's
clinical status (Fig. 2),
Noninvasive hemodynamic variables and plasma beta.
endorphin levels . The clinical characteristics and plasma
beta-endorphin levels of the 17 patients with dilated cardio-
myopathy are shown in Table I ;
there were 15 men and 2
wnmen, aged 24 to 76 years . Eight patients were in furtc-
tional class 1L five were in class 111 and four were in class
IV . Plasma levels of hela-endorphin were correlated with
functional cardiac status
(class
IC 16.0'- 1 .8
girl:
class Ill :
26 .5 ± 10.3 pgiml; class IV : 48.3 -_ 13 .1 pglml : p r 0 .01 for
class 11 versus IV and class II versus IV).
llenlvdvnamic eats en
ar rest a -err esatnined jar corre)a-
rian svirh plasma hero-endorphin levels . The patients exhib-
ited decreased left ventricular performance with a large left
ventricle. Neither blood pressure nor heart rate correlated
with plasma beta-endorphin levels. Index of left ventricular
systolic function did not correlate with plasma beta-
endorphin it = -0.429 for FS . -0 .328 for mean Vcf and
0.116 for pre-ejection periodlleft ventricular ejection time)
I(AWASHIMA ET AL .
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Figure 2 . Charges in plasma beta-endorphin levels during a fol-
low-up period of 2 moths in eight patients with congestive heart
failure. Open circles represent plasma beta-endorphin levels on
admission and cloud circles those obtained 2 months later.
(Fig . 31 . Neither let( ventricular end-diastolic nor end-
systolic dimension correlated with plasma beta-endorphin
level Ir = 0.226, and 0.330. respectively) (Fig. 4) . The ratio
of early to late peak flow velocity during diastole in the
Doppler transmittal flow pattern was measured in 11 patients
with sinus rhythm and showed no correlation with plasma
beta-endorphin if = - 0.027) . A negative correlation was
noted between betaendorphin levels and Doppler-derived
cardiac output (r = -0.743) (Fig. 5). There was a positive
correlation between belaendorphin levels and systemic vas-
cular resistance (r = 0.747). There was no correlation
between beta-endorphin levels and calf blood flow (r
-0
.4221
.
Exercise capacity and plasma beta-endorphin. Basal
plasma beta-endorphin levels were closely correlated with
exercise capachy (Fig- 6) . The higher the plasma levels . the
lower the exercise capacity . This good correlation could still
h
e o
bs
erved after excluding patients older than 70 years to
minimize age-related varinhithy in exercise performance
(15). After the exclusion . the correlation with peak oxygen
consumption, anaerobic threshold and peak rate-pressure
product were r =
-0.770(p < 0
.01) . -0.659 4p < O.Ot), and
-0 .677 (p a 0-05), respectively .
Discussion
The present study shows that plasma levels of beta-
endorphin are elevated in patients with congestive heart
failure This is in agreement with previous experimental data
(10 .111 obtained from conscious dogs with congestive heart
failure . Plasma beta-ondorphin levels also correlated with
functional cardiac status and exercise capacity .
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BP = blood pressure ; F = female : HR = heart rate: M = male.
Seerefion of beta-endorphin.
The precursor of beta-
endurphin is pro-apiotnelanocortin, a common precursor with
adrenocorticotropin (ACTH), and mainly located
in the pitu-
itary gland (1-3)
.
Bela•e
stdorphin and adrenoccrticotropin are
released together into the peripheral circulation from the pitu-
itary gland in response to various stresses (1-3,9). In addition
to stress, plasma beta-endorphin levels are regulated by circa-
dian rhythm and a negative feedback system (1,2 .5,9) . INeuro-
humoral factors such as corticotropin-releasing factor and
calecholamines are believed to be involved in the secretion of
beta-endorphin from the pituitary gland during stress . It has
been reported that plasma levels of beta-endorphin increase
during a hypovulemic state
(4,16) . Therefore, although the
precise mechanism is unclear. underperfusion in various tis-
sues probably acts to stimulate secretion of tseea-endorphin in
patients with heart failure .
Bell-endorphinandcardiovaseularfuacrion . Sympathetic
nervous activity is augmented in hear[ failure (17-20) . Al-
though the heightened adrenergic drive may play a detrimen-
rat role in the late phase of heart failure, it operates to
compensate for hemodynamic abnormalities in heart failure
.
Endogenous opioids such as beta-endorphin are closely
0
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Figure 3. Lack of correlation of plasma beta-endorphin levels with
indexes of left ventricular performance at rest. LVET = left
ventricular ejection time ; mean VM = mean rate of circumferemial
shortening ; PEP = pre-ejection period .
Figure 4. Lack of correlation of plasma beta-endorphin level with
left ventricular end-diastolic and
end-systolic
dimensions and ratio
of early to late peak velocity WA ratio) during diastole in the
transmittal Doppler flow pattern.
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Table I . Characteristics of 17 Patients with Cardiomyopathy
Grouped According to Cardiac Functional Class
Pt. Age BP
Plasm4
M.-
Endorphin
N6. Irrl
Sea HR lbeatc/minl Imm 11PPI Iggim0
CIassIf
1 65 M
56 116174 14
.8
2 58 M 82 114170 16.8
3 42 F 71 126384 14.6
4 42 61
74 12286
13.0
5 55
1,
65 13054 16.4
6 37 M 72 118372 17.0
72
h1 60 H I/HI 14.4
8 41 F 76 131/38 lit
Mean 51 .3
71 .6 1630
SD 12 .8 5 .6 1 .8
Clus III
9 56 M 68 99/60 Si!
10 56 M 80 11078 13.6
11 44 M 70 12070 41 .6
12 76 M 68 IIW66 29 .0
13 42 M 70 11046 25 .5
Mean 54 .1 71 .2 26.5
SD 13 .5 5 .0 10.3
Class IV
14 6S 61 86 110169 56A
IS 54 M 68 106170 62.0
16 24 M 104 96876 34 .0
17
74
M 96 156192 40 .9
Mean 54 .3 483 48 .3
SD 21 .8 15 .5 13 .1
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Flgtre5. Correlation ofplacmaheta-endorphinwdhcard iacasIpul
at rest. systemic vascular resistance and calf blood nun,
related to the sympathetic nervous system both in brain and
peripheral tissues (4 .21) . Liang el al (10) demonstrated that
nalmefene, an opioid receptor antagonist, increased cardiac
output and improved tissue perfusion mainly by neutralizing
the inhibitory action of opioids on the sympathetic nervous
system in dogs with heart failure. Recent studies (22) also
show that endogenous opioids exert local depressant effects
on the heart. Thus, increased beta-endorphin may be a
deleterious factor in congestive heart failure accompanied by
an activated sympathetic nervous system.
Relation to
cardiovascular function
. To examine whether
plasma beta-endorphin contributes to hemodynamic abnor-
mality in congestive heart failure, a correlation between
plasma beta-endorphin levels and cardiovascular function
was sought . For the assessment, dilated cardiomyopathy
was chosen because it has characteristics relatively typical
of impaired ventricular function and was believed suitable
for echocardiographic assessment of ve,itricular shape .
Plasma endorphin levels did not correlate with any variable
of left ventricular function. including ventricular contractil-
ity . Thus, elevated plasma beta-endorphin levels do not play
a major role in the control of ventricular function in patients
with heart failure . Plasma beta-endorphin levels were posi-
tively correlated with systemic vascular resistance and neg-
atively with cardiac output, Therefore. either hypoperfusion
may function as a stimulus of beta-endorphin release or
beta-endorphin may contribute to hypoperfusion as reflected
by decreased cardiac output and increased systemic vascular
resistance i n congestive heart failure Opioid receptor antag-
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Ci-relatiun of
plasma beta-endorphin with indexes of
s urn c i se performance during treadmill exercise testing,
onins have been shown (4-6) to increase cardiae output and
decrease systemic vascular resistance in various types of
shack . A study using an opioid receptor antagonist should be
cunductad to clarify the causal role of beta-endorphin for the
hypoperfusion in heart failure .
Beta-endorphin and exercise capacity . Plasma beta-
endorphin levels were correlated with exercise capacity as
expressed by peak oxygen consumption, anaerobic thresh-
old, and perk rate-pressure product
. Exercise capacity is a
realistic index of clinical disability and prognosis in patients
with heart failure (23 .24). Therefore, the good correlation of
plasma beta-endorphin levels with exercise capacity and
functional cardiac status suggests that heta-endorphin levels
are a marker of the severity of bean failure
(25) .
Although a good correlation was noted between exercise
capacity and plasma levels of beta endorphin, cause and
effect cannot he inferred . Beta-endorphin levels increase
during esereise, and this may be related to perception of train
and regulation of ventilation during exercise (26,27) . But
whether increased plasma beta-endorphin levels influence
exercise capacity in heart failure remains unclear, Naloxone,
an opiate receptor antagonist, fails to modify exercise per-
formance in healthy men (28-241, but no information is
available as to whether naloxone can alter exercise tolerance
in patients with congestive heart failure . Conversely, in-
creased plasma levels of beta-endorphin may simply reflect
the severity of heart failure . Further studies are needed to
clarify the rote of beta-endorphin as a factor determining
exercise capacity in patients with congestive heart failure
.
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Conclusions
. In recent years, increasing attention has
been directed to the neurohumoral factors in congestive
heart failure ; these factors contribute importantly to the
symptoms of heart failure . Plasma beta-endorphin levels are
elevated in patients with congestive heart failure . Along with
other neurohumoral factors, plasma beta-endorphin levels
reflect the severity
of
congestive heart failure
. Plasma beta-
endorphin levels were shown to be correlated with cardiac
functional status and exercise capacity . Whether beta-
endorphin can serve as a marker of patient prognosis, as in
the cast of norepinephrine . remains to be determined .
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